Low dose interferon alfa-2b for chronic hepatitis B in Asian countries
- PMID: 8314500
- PMCID: PMC1374023
- DOI: 10.1136/gut.34.2_suppl.s99
Low dose interferon alfa-2b for chronic hepatitis B in Asian countries
Abstract
In a study of low dose interferon alfa-2b in 587 patients expected to show a good response to treatment, 76-87% patients in different countries had alanine amino-transferase activities returned to normal after four months' treatment, 49-72% were negative for hepatitis B virus (HBV)-DNA, 51-66% were negative for hepatitis B e antigen (HBeAg), and 44-62% were anti-HBe positive. These effects were maintained after nine to 12 months' follow up. Side effects were mild, but led to discontinuation of treatment in 12 patients.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical